NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact...
NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to...
NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact...
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company’s...
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following...
The law firm of Kirby McInerney LLP is investigating potential claims against Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT). The investigation concerns whether the Company...
Certara (NASDAQ:CERT) reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a...
RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter...
Barchart Research What to Expect from CERT Earnings CERT Generated May 8, 2026 Current Price $6.29 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 9.84% Certara's First Quarter Report Arrives...
Barchart Research What to Expect from CERT Earnings CERT Generated May 8, 2026 Current Price $6.29 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 9.84% Certara's First Quarter Report Arrives...